Research programme: cytomegalovirus vaccines - Pfizer

Drug Profile

Research programme: cytomegalovirus vaccines - Pfizer

Alternative Names: Cytomegalovirus reVLPs®; Cytomegalovirus VLPs - Redbiotec; RBT 301; RBT 302; RBT 303; RBT 304; RBT 305; RBT 306

Latest Information Update: 19 Jul 2016

Price : $50

At a glance

  • Originator Redbiotec; Redvax
  • Developer Pfizer
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cytomegalovirus infections

Most Recent Events

  • 28 Jul 2014 Development is ongoing in Switzerland
  • 11 Jul 2014 Preclinical trials in Cytomegalovirus infections in Switzerland (Parenteral)
  • 11 Jul 2014 Immunogenicity data from preclinical studies in Cytomegalovirus infections released by Redbiotec
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top